BioSpace News Archive

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the appointment of Dr. Charles McWherter as President of Research and Development.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported third quarter 2022 financial results and provided a corporate update.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel viral immunotherapies, announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November.

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that subject screening for the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% is complete, allowing for a topline data announcement target of 2Q-2023.

Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, announced that Cingal® met its primary endpoint in a Phase III Study, demonstrating superiority over triamcinolone hexacetonide steroid alone at 26 weeks post-treatment.

Olema Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences in November.

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that setmelanotide received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of hypothalamic obesity.

A new study published in JAMA demonstrated that patients at high risk for acute kidney injury, the most common complication of percutaneous coronary intervention, had a significant reduction in AKI when cardiologists used Terumo Health Outcomes’ ePRISM clinical decision support platform.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid tumor targeting TriNKET developed by Dragonfly.